Compare AWK & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWK | NTRA |
|---|---|---|
| Founded | 1886 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 28.0B |
| IPO Year | 2007 | 2015 |
| Metric | AWK | NTRA |
|---|---|---|
| Price | $133.81 | $207.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $140.00 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | ★ 5.57 | 0.65 |
| EPS | ★ 5.69 | N/A |
| Revenue | ★ $3,011,328,000.00 | $210,939,000.00 |
| Revenue This Year | $6.09 | $18.08 |
| Revenue Next Year | $6.90 | $19.72 |
| P/E Ratio | $23.11 | ★ N/A |
| Revenue Growth | ★ 3.77 | N/A |
| 52 Week Low | $121.28 | $131.81 |
| 52 Week High | $150.51 | $256.36 |
| Indicator | AWK | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 52.71 |
| Support Level | $130.76 | $186.89 |
| Resistance Level | $134.41 | $220.33 |
| Average True Range (ATR) | 3.15 | 10.07 |
| MACD | -0.68 | 0.97 |
| Stochastic Oscillator | 47.64 | 66.12 |
American Water Works is the largest investor-owned US water and wastewater utility, serving nearly 4 million customers in 14 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns. The proposed Essential Utilities acquisition would add regulated water and wastewater utilities in Ohio, North Carolina, and Texas while increasing its presence in Illinois, Indiana, Pennsylvania, New Jersey, and Virginia.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.